Skip to main content
Skip to content
1 duplicate copy in the archive
Case File
d-18918House Oversight

Fund Prospectus Detailing Structured Investments in Biopharma Companies

Other

The passage is a marketing/strategic document describing past and planned investments in small‑cap biopharma firms. It contains no allegations, no mention of high‑ranking officials, no financial misco Lists prior exits: Sprout IX (sold to Merck), Array Pharmaceuticals (2.25x), Acadia Pharmaceuticals Describes investment thesis for a new fund (NLV‑III) focused on targeted therapeutics and biomarke

Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #024046
Pages
1
Persons
4
Integrity
No Hash Available
Loading document viewer...

Ask AI About This Document

0Share
PostReddit
Review This Document

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.